Negative regulation of transcription by the type II arginine methyltransferase PRMT5-Reference-Cited by-同舟云学术

Negative regulation of transcription by the type II arginine methyltransferase PRMT5

Published:2002-07 Issue:7 Volume:3 Page:641-645
ISSN:1469-221X
Container-title:EMBO reports
language:en
Short-container-title:EMBO Rep

Author:

Fabbrizio Eric¹,Messaoudi Selma El¹,Polanowska Jolanta¹,Paul Conception¹,Cook Jeffry R²,Lee Jin‐Hyung²,Nègre Vincent¹,Rousset Mathieu³,Pestka Sidney²,Le Cam Alphonse¹,Sardet Claude¹

Affiliation:

1. Institut de Génétique Moleculaire, UMR 5535/IFR24, CNRS 1919 Route de Mende 34293 Montpellier cedex 5 France

2. Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School Piscataway NJ 08854‐5635 USA

3. CRBM/IFR24, CNRS 1919 Route de Mende 34293 Montpellier cedex 5 France

Publisher

EMBO

Subject

Genetics,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1093/embo-reports/kvf136

Reference25 articles.

1. Methylation at arginine 17 of histone H3 is linked to gene activation

2. PRMT5 (Janus Kinase-binding Protein 1) Catalyzes the Formation of Symmetric Dimethylarginine Residues in Proteins

3. Retinoblastoma protein recruits histone deacetylase to repress transcription

4. Regulation of Transcription by a Protein Methyltransferase

5. Cyclin A Is a Mediator of p120 E4F -Dependent Cell Cycle Arrest in G 1

Cited by 198 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Histone Arginine Methylation as a Regulator of Gene Expression in the Dehydrating African Clawed Frog (Xenopus laevis);Genes;2024-09-01

2. Genetic screen identified PRMT5 as a neuroprotection target against cerebral ischemia;eLife;2024-02-19

3. PRMT5 orchestrates EGFR and AKT networks to activate NFκB and promote EMT;2024-01-04

4. Genetic Screen Identified Prmt5 as a Neuroprotection Target against Cerebral Ischemia;ELIFE;2023-11-15

5. The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality;Frontiers in Oncology;2023-09-19